InSite Vision announced results from its Phase 1/2 study of ISV-303 for the reduction of pain and inflammation associated with ocular surgery. The exploratory study enrolled 169 patients undergoing cataract surgery and was designed to evaluate the absence of cells in the anterior chamber of the eye at 15 days post surgery. ISV-303 demonstrated statistically significant results over the DuraSite vehicle (53.3% vs. 19%; p=0.0016) and numeric superiority over Xibrom (bromfenac ophthalmic solution; ISTA) 0.09% (53.3% vs. 42.2%).
ISV-303 contains topical bromfenac 0.075%, a non-steroidal anti-inflammatory, and InSite’s proprietary DuraSite drug delivery vehicle.
For more information call (510) 865-5700 or visit www.insitevision.com.